An act to add Section 11112 to the Health and Safety Code, relating to controlled substances.
SB 1306 would add a new section to the Health and Safety Code creating an exemption for certain chemical mixtures containing gamma-butyrolactone (GBL) from California’s controlled precursor chemical permitting, reporting, and bill-of-sale requirements. The exemption would apply when GBL is present in a mixture at 70 percent or less by weight or volume and the mixture contains at least one other non-inert substance. The bill also specifies that the exemption covers mixtures obtained, received, sold, transferred, exported, or otherwise furnished within or outside California, so long as the regulatory requirements would be triggered solely because of the GBL content.
The bill’s findings frame the change as an effort to align California law with federal DEA rules that already exempt certain GBL mixtures and to reduce compliance burdens on semiconductor manufacturers and other advanced manufacturers. The Legislature states that GBL is used in semiconductor fabrication and that California’s current rules are more restrictive than those in other major manufacturing states, creating unnecessary administrative and enforcement costs without corresponding public-safety benefits.
If enacted, SB 1306 would narrow the reach of existing Health and Safety Code sections 11100, 11100.1, 11103, 11106, and 11107 as applied to qualifying GBL mixtures. That would reduce permitting, reporting, theft/loss reporting, and bill-of-sale obligations for affected manufacturers, wholesalers, retailers, and other sellers or transferors of those mixtures. The bill would not remove regulation of GBL generally, but it would carve out a defined industrial-mixture category from the current precursor-chemical framework.
The overall sentiment reflected in the bill text and vote history appears favorable and industry-oriented. The measure advanced on a 6-0 committee vote to be re-referred to Appropriations, suggesting no recorded opposition at that stage. The findings emphasize economic competitiveness, semiconductor supply chains, and consistency with federal standards, indicating the bill is being presented as a targeted regulatory relief measure rather than a broad rollback of controlled-substance oversight.
The main point of contention is the balance between reducing regulatory burdens for industrial users and maintaining controls on a chemical associated with diversion risk. Supporters’ rationale is that the federal government already treats low-concentration GBL mixtures differently and that California should conform to that approach for manufacturing uses. Potential critics may be concerned that exempting GBL-containing mixtures could weaken oversight or create enforcement ambiguity, although no specific opposition is reflected in the provided materials.
SB 1306 would add Health and Safety Code Section 11112 to exempt qualifying chemical mixtures containing gamma-butyrolactone from several state precursor-chemical requirements, including permitting, reporting, theft/loss reporting, and bill-of-sale obligations, when those requirements would apply solely because of the GBL content. The bill would therefore narrow the application of existing controlled-substance precursor statutes to industrial mixtures containing 70 percent or less GBL by weight or volume, affecting manufacturers, wholesalers, retailers, and other handlers of those mixtures, especially in semiconductor and advanced manufacturing supply chains.
The bill appears generally supportive and pro-industry in tone. Its findings emphasize semiconductor manufacturing, economic competitiveness, and alignment with federal exemptions, and the available vote history shows unanimous committee support in the recorded vote. No committee transcript opposition is provided, so the public record supplied here suggests limited visible resistance at this stage.
The central policy tension is between easing regulatory burdens for industrial users of GBL and preserving state oversight of a controlled precursor chemical. Supporters argue California’s current rules are out of step with federal standards and impose unnecessary costs on semiconductor manufacturers. Any opposition would likely focus on whether the exemption could reduce monitoring of a chemical with diversion potential or create a broader loophole in precursor-chemical enforcement, though no explicit opposing arguments are included in the provided materials.